Literature DB >> 26826542

Geographical disparities in prescription practices of lithium and clozapine: a community-based study.

H Verdoux1,2, E Pambrun1,2, S Cortaredona3,4,5, M Coldefy6,7, C Le Neindre6, M Tournier1,2, P Verger3,4,5.   

Abstract

OBJECTIVE: To explore the socioeconomic and health resource characteristics associated with geographical variations of lithium and clozapine dispensing rates in France.
METHOD: The study was performed using reimbursement data from the French Insurance Healthcare system over the period 2006-2013 in a community-based sample of persons aged 16 years and over. An ecological design was used to assess whether lithium and clozapine prescribing rates were associated with socioeconomic and health resource characteristics of the zone of residence (n = 95 French administrative subdivisions).
RESULTS: Large geographical disparities were observed in dispensing rates: lithium dispensing rates by zone of residence ranged from 0 to 6.6 per 1000 (mean 2.4 per 1000) and clozapine dispensing rates ranged from 0 to 4.9 per 1000 (mean 0.8 per 1000). Higher density of GPs and regular communication between mental health services and primary care were independently associated with higher rates of lithium and clozapine dispensing and with a higher proportion of lithium users among mood-stabilizer users.
CONCLUSION: A sufficient density of GPs and an effective communication and collaboration between mental healthcare services and primary care seems to favor greater access to psychotropic drugs with demonstrated efficacy but often viewed as 'risky' to prescribe.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  clozapine; geographical variations; health insurance database; lithium

Mesh:

Substances:

Year:  2016        PMID: 26826542     DOI: 10.1111/acps.12554

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  5 in total

1.  Safety of psychotropic medicines: contribution from observational evidence.

Authors:  H Verdoux
Journal:  Epidemiol Psychiatr Sci       Date:  2018-05-30       Impact factor: 6.892

2. 

Authors:  Marta H Costa; Mauricio Kunz; Andrew A Nierenberg; Thilo Deckersbach; Michael Berk; Pedro V S Magalhaes
Journal:  Can J Psychiatry       Date:  2020-01-21       Impact factor: 4.356

3.  Clinical correlates of augmentation/combination treatment strategies in major depressive disorder.

Authors:  M Dold; L Bartova; J Mendlewicz; D Souery; A Serretti; S Porcelli; J Zohar; S Montgomery; S Kasper
Journal:  Acta Psychiatr Scand       Date:  2018-02-28       Impact factor: 6.392

4.  Prescription and Underprescription of Clozapine in Dutch Ambulatory Care.

Authors:  Yvonne C van der Zalm; Fabian Termorshuizen; Peter F Schulte; Jan P Bogers; Machteld Marcelis; Iris E Sommer; Jean Paul Selten
Journal:  Front Psychiatry       Date:  2018-06-11       Impact factor: 4.157

5.  The Patient-Reported Experience Measure for Improving qUality of care in Mental health (PREMIUM) project in France: study protocol for the development and implementation strategy.

Authors:  Sara Fernandes; Guillaume Fond; Xavier Zendjidjian; Pierre Michel; Karine Baumstarck; Christophe Lancon; Fabrice Berna; Franck Schurhoff; Bruno Aouizerate; Chantal Henry; Bruno Etain; Ludovic Samalin; Marion Leboyer; Pierre-Michel Llorca; Magali Coldefy; Pascal Auquier; Laurent Boyer
Journal:  Patient Prefer Adherence       Date:  2019-01-21       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.